References in periodicals archive ?
The Company will present data from the most recent Phase II clinical trial of SomatoKine(R) for the treatment of type 2 diabetes and the Company will present two additional posters that will detail the results of additional analyses from previously reported clinical trial data with INS-1 in type 2 diabetes.
In clinical trials to date, INS-1 has demonstrated improved glycemic control and a superior safety profile to existing oral insulin sensitizers.
In patients with type 2 diabetes, INS-1 significantly improves glycemic and lipid profiles with no evidence of any major side effects.
Insmed Incorporated (Nasdaq: INSM) today announced that three abstracts will be presented at The Endocrine Society's 84th Annual Meeting, ENDO 2002, detailing recent research with two of its lead compounds, SomatoKine(R) and INS-1.
Insmed Incorporated (Nasdaq: INSM) will conduct two poster sessions at the American Diabetes Association's 61st Annual Scientific Sessions, detailing the safety and efficacy of each of its two lead compounds, INS-1 and SomatoKine(R).
Despite strong demand for existing agents, most have less than optimal side effect profiles, creating a significant market opportunity for both INS-1 and SomatoKine.
The collaborative study involves collecting blood samples and phenotypic data from subjects that have been diagnosed with PCOS who are currently enrolled in clinical trials designed to evaluate the effects of Insmed's product candidate INS-1 and additional control subjects who do not have PCOS.
INS-1, a naturally occurring, oral, insulin sensitizer, is believed to be an essential component of a molecule that activates the key enzymes controlling glucose metabolism in people who are insulin resistant.
In clinical trials to date, INS-1 has significantly improved ovulation rates in women with PCOS, as well as glycemic control parameters and lipid profiles in Type 2 diabetics.
Net proceeds from the offering will be used to fund development of INS-1 and SomatoKine, as well as for working capital, capital expenditures and general corporate purposes.
The company also reported that a trial of INS-1 in patients with Polycystic Ovary Syndrome (PCOS) and a trial in patients with dyslipidemia were completed on schedule.
The two abstracts presented to the ADA will detail the efficacy of both of the company's lead compounds, INS-1 and SomatoKine.